Introduction
============

The risk of blood-borne pathogens in coagulation factor concentrates has been virtually eliminated by the introduction of effective virus inactivation procedures for plasma-derived concentrates and the development of recombinant factor concentrates. At present, the development of inhibitors is the most serious complication to the use of these concentrates in hemophilia care, and patients with inhibitors represent a major therapeutic challenge. Inhibitors develop in 20--30% of patients with severe hemophilia A \[factor (F) VIII levels \<1%\] and in 5% or less of patients with severe hemophilia B (FIX levels \<1%) ([@b35]; [@b46]; UK Haemophilia Center Doctors' Organization [@b44]). Inhibitors may occasionally also develop in patients with mild or moderate hemophilia. Inhibitors are inhibiting or neutralizing alloantibodies to FVIII/FIX which usually develop after 10--20 exposures to FVIII/FIX concentrates. Inhibitors may be transient or resolve with immune tolerance therapy (ITI), but in 10--15% of hemophilia A patients inhibitors remain clinically significant (high-titer). ITI is far less successful in managing FIX inhibitors than FVIII inhibitors ([@b19]).

Inhibitors to FVIII/FIX preclude the use of standard and effective factor concentrates. Although bleeds do not occur more frequently than in non-inhibitor patients, the bleeds may be much more difficult to control, and the presence of inhibitors increases the risk of uncontrollable bleeding, disability and premature death ([@b41]; [@b44]). Progressive and disabling joint disease is more prevalent in inhibitor patients than in non-inhibitor patients ([@b24]).

Acquired hemophilia is a rare condition characterized by the development of neutralizing or inactivating autoantibodies to FVIII in patients with previously normal FVIII levels. An incidence of 0.2--1 patient per million persons per year has been reported ([@b38]; [@b26]; [@b13]). The disease usually develops late in life, and it is associated with high morbidity (life-threatening bleeds in more than 85% of patients) and high mortality varying from 8% to 22% (Green and Lechner 1981; [@b10]; [@b5]). Although the clinical phenotype of acquired hemophilia differs from that of congenital hemophilia, managing bleeds poses more or less the same challenges to the clinician.

Inhibitors are measured with the Bethesda assay or its modifications, and titers are expressed in Bethesda units (BU).

The development of inhibitors is the most pressing concern in hemophilia care to day, and there is great interest in methods to reduce the risk of inhibitor development, improve on immune tolerance therapy regimens, treat bleeds, provide hemostasis during surgery and develop effective laboratory methods to assess bypassing therapy. In this review we will focus on the management of bleeds and the prevention of chronic joint disease.

Treatment of bleeds
===================

Apart from the severity and location of the bleed, the characteristics of the inhibitor are the most important factors to consider in the management of a bleeding episode in a particular patient. Treatment options are dependent on the inhibitor titer as well as whether the inhibitor is low or high responding. Knowledge of the patient's previous response to specific therapies also provides important information selecting the best hemostatic therapy. Approximately 70% of the inhibitors in hemophilia A patients are due to high-responding antibodies which show a substantial rise in titer (5 BU or higher) within 4--6 days of exposure to FVIII (anamnestic response). In hemophilia B more than 80% are of the high responder type. Low-responding inhibitors (generally \<5 BU) are not anamnestic, and they are much more likely to be transient. A bleed in a low-titer, low-responder patient can usually be treated by standard factor concentrates, but much higher doses than in non-inhibitor patients have to be used to overcome the inhibitor. In general, standard factor concentrates, even in higher doses, are not effective in patients with high-titer inhibitors. Hemostatic agents with proven efficacy in the treatment of bleeds in inhibitor patients are presented in [Table 1](#tbl1){ref-type="table"}. However, only bypassing agents are currently available. Prothombin complex concentrates (PCCs) and activated prothrombin complex concentrates (aPCCs), plasma-derived products containing FII, FVII, FIX, FX and small amounts of FVIII, have been available for the treatment of inhibitor patients for more than 30 years. aPCCs, in contrast to PCCs, contain activated FVII and small amounts of activated FII, FIX and FX. PCCs have been shown to be less effective than aPCCs and to show a higher rate of adverse reaction ([@b39]; [@b27]; [@b30]). Currently, PCCs are seldom used to treat inhibitor patients. In the 1990s, recombinant activated FVII (rFVIIa) concentrate were introduced for treatment of inhibitor patients. In clinical trials both aPCCs (factor right inhibitor bypass activity, \[FEIBA\]; Baxter AG, Vienna, Austria) and rFVIIa (NovoSeven, Novo Nordisk AS, Bagsværd, Denmark) have shown excellent efficacy (80--90%) in the management of bleeding in inhibitor patients ([@b11]; [@b17]). The hemostatic actions of these agents are different and still not fully unraveled. Nevertheless, both products appear effective, safe and well tolerated, but clinical evidence from randomized, prospective trials comparing the two agents as a guide to their optimal use in inhibitor patients are still lacking. There are ongoing studies addressing this issue, but the final reports are still pending.

###### 

Coagulation factor concentrates with proven efficacy in hemophilia patients with high-titer inhibitors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factor concentrate   Advantage                                  Disadvantage                                                                                                       Comments
  -------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Porcine (p) FVIII    Measurable FVIII levels                    Inhibitors often show cross-reactivity with pFVIII or the patients develop pFVIII after 5--10 days of treatment\   Plasma derived pFVIII are presently not available\
                                                                  Risk of transmission of porcine viruses                                                                            A recombinant pFVIII concentrate is in clinical development

  PPCs                 Bypass the need for FVIII\                 Inferior efficacy compared to aPCCs\                                                                               aPCCs have supplanted the use of PCCs
                       Relatively inexpensive                     Potentially thrombogenic\                                                                                          
                                                                  High frequency of infusion related adverse events                                                                  

  aPCCs                Long history of use\                       Unpredictable hemostatic response\                                                                                 The risk of thrombotic complications with standard doses is low\
                       Efficacy of 80--90% in clinical trials\    Potentially thrombogenic\                                                                                          Increase in inhibitor titer does not hamper efficacy
                       Long-half life compared to rFVIIa\         Trace amounts of FVIII leading to anamnesis of the inhibitor\                                                      
                       More effective than PCCs\                  Possibility of transmission of human viruses\                                                                      
                       Cost advantage over rFVIIa                 No established laboratory assay to monitor efficacy and optimal dosing                                             

  rFVIIa               Efficacy in 80--90% in clinical trials\    Unpredictable hemostatic response\                                                                                 The risk of thrombotic complications is low\
                       No anamnestic response\                    Potentially thrombogeneic\                                                                                         Whether the risk of thrombotic complications differ significantly between aPCCs and rFVIIa is an unresolved issue
                       No risk of transmission of human viruses   No established laboratory assay to monitor efficacy and optimal dosing\                                            
                                                                  Short half-life making rFVIIa less convenient than aPCCs                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The FENOC (The FEIBA versus NovoSeven Comparative Study) study compared the hemostatic effect of FEIBA on joint hemorrhages with that of rFVIIa. The main objective was to compare the efficacy of a single dose of FEIBA (target dose, 85 IU/kg bw) with two doses of rFVIIa (target dose, 105 μg/kg bw), and enrollment was stopped in December 2004. Preliminary results show that the treatment was effective in 80.9% and 78.7% of the patients with FEIBA and rFVIIa, respectively ([@b3]). The study also show that a significant number of patients report a better effect of one or the other of the products. A second study is addressing whether a single high dose (270 μg/kg) of rFVIIa is more effective than the currently approved dosing (90 μg/kg for 3 doses). Data from uncontrolled trials suggest that higher doses of rFVIIa are more effective than standard dose ([@b16]; [@b37]). The results from the prospective, randomized study are pending.

Some patients do not respond well to either FEIBA or rFVIIa. The combined use of FEIBA and rFVIIa has been put forward as an approach for bleeds that are refractory to either agent alone ([@b18]). A recent case report on the use of sequential therapy with FEIBA and rFVIIa demonstrated the efficacy and safety of this approach ([@b36]). However, the issue of concomitant use of FEIBA and rFVIIa is a matter of dispute among hematologists ([@b2]).

Several clinical features distinguish FIX inhibitors from FVIII inhibitors. With respect to treatment of bleeds, anaphylaxis or anaphylactoid reactions to FIX-containing concentrates are, although rare, the most important feature in terms of morbidity. A history of anaphylaxis to FIX-containing concentrates was recently shown in a majority of hemophilia B patients with high-titer inhibitors, and rFVIIa seems to be a suitable treatment of choice in these patients ([@b46]; [@b19]).

Prophylaxis
===========

In non-inhibitor patients prophylactic treatment with coagulation factor concentrates prevents bleeding and resultant joint damage ([@b31]; [@b8]; [@b20]). Currently, prophylaxis from early childhood to prevent end-stage joint disease is recommended in most western countries. Inhibitor patients have an even greater probability of developing disabling joint disease than non-inhibitor patients ([@b24]). Accordingly, the possibility of prophylaxis with bypassing agents in inhibitor patients is a matter of concern for the hemophilia community. Several small studies suggest that daily or every-other-day doses of FEIBA of less than 100 IU/kg/day are safe ([@b23]; [@b21], [@b22]; [@b7]; [@b45]; [@b12]; [@b7]). The studies show a reduction in the number of annual bleeds, but the results regarding the prevention of progressive joint damage are equivocal ([@b12]). There are two reports describing prophylaxis with rFVIIa in three patients resulting in reduction in severe bleeds and reduced hospitalizations ([@b34]; [@b48]). At present, a recommendation of prophylaxis with bypassing agents in inhibitor patients is not supported by solid clinical evidence. There is an on-going study evaluating the efficacy of FEIBA for prophylaxis in inhibitor patients (PRO-FEIBA study). The primary objective of the trial, which has a cross-over design, is \>50% reduction in the number of bleeds during a 6-month period with prophylaxis compared to on-demand therapy.

Monitoring therapeutic efficacy
===============================

There is no generally accepted laboratory assay to monitor efficacy or determine an optimal dose of the bypassing agents ([@b25]; [@b29]). However, both thromboelastography (TEG) and thrombin generation assay (TGA) may provide some guidance in the treatment of the individual patient. Using these assays it is clearly demonstrated that the ex vivo responses to both bypassing agents are dose-dependent ([@b14]; [@b43]; [@b40]). It is well appreciated that there is a considerable variation in clinical phenotype among patients with severe hemophilia, and this is reflected by a variation in the results of in vitro testing of hemostatic intervention ([@b14]). A good in vitro response to rFVIIa usually predicts a similar response to FEIBA, but discrepancies are observed in some patients ([@b14]; [@b40]). One of our inhibitor patients failed post-surgical prophylaxis with FEIBA following a total knee arthroplasty. He was successfully rescued by rFVIIa. Ahead of a scheduled arthroplasty of the other knee, we have performed in vitro testing of the hemostatic efficacy of FEIBA and rFVIIa by TEG in collaboration with Sørensen and Ingerslev (Center for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark). rFVIIa corresponding to a 100 μg/kg dose normalized the patient's clotting profile. FEIBA corresponding to a 100 IU/kg dose did not normalize the patient's clotting profile, but the clotting profile was normalized by increasing FEIBA corresponding to a 200 IU/kg dose. In the post-surgical prophylaxis setting this would result in a daily dose of FEIBA high above the maximum recommended dose (200 IU/kg/day). Dargaud et al have recently used the TGA to tailor the hemostatic treatment during major surgery in an inhibitor patient in whom rFVIIa was ineffective treating muscle and joint bleeds ([@b4]).

FEIBA: mode of action
=====================

Testing plasmas deficient in different coagulation factors using TGA, Turecek et al showed that FEIBA improves thrombin generation in all plasmas, except FV-deficient plasma ([@b42], [@b43]). Similar results were accomplished by a complex consisting of activated FX and prothrombin indicating that FXa and prothrombin are the constituents of FEIBA providing the hemostatic efficacy ([@b42], [@b43]).

Adverse effects
===============

FEIBA is usually well tolerated. Infusion-related adverse events like fever, hives and bronchial spasms are rare (\<0,04%) ([@b6]). FEIBA contains trace amounts of FVIII which may produce an anamnestic response. The first report on this phenomenon appeared in 1977 ([@b32]). Kasper reported a rise in inhibitor level to at least twice the pretreatment value in 21% of patients following the first exposure of prothrombin complex concentrates, and the proportion of patients who mounted an anamnestic response decreased with the number of exposures ([@b15]). An anamnestic response to FVIII does not seem to influence the efficacy of FEIBA, and Hilgartner et al reported more recently that the inhibitor titre decreased during long-term FEIBA prophylaxis ([@b12]). FEIBA is a vapour-heated plasma-derived coagulation factor concentrate and a potential for viral transmission exists. Today, no confirmed reports of human immunodeficiency virus, hepatitis A, hepatitis B or hepatitis C transmission have been published.

FEIBA as well as rFVIIa have been associated with thromboembolic complications and disseminated intravascular coagulation (DIC). The most serious complications are myocardial infarction and cerebral infarction. These are rare events associated with large and repeated doses that in most cases exceeded the recommended doses ([@b7]). There is an on-going dispute whether the risk of thromboembolic complications differs between FEIBA and rFVIIa ([@b1]; [@b28]; [@b33]).

Conclusion
==========

The development of high-titer inhibitors to FVIII and less often to other coagulation factors makes treatment of patients with severe bleeding disorders difficult. Although bypassing agents, such as FEIBA and rFVIIa, are effective and safe in controlling bleeding in inhibitor patients, their efficacy is not considered equal to that of coagulation factor replacement in patients without inhibitors. Improvements of hemostatic therapies for inhibitor patients are warranted. Patients with high-titer inhibitors are prone to serious bleeding episodes and development of debilitating joint disease, and many physicians still are reluctant to perform surgery in these patients.

Conflict of interest
====================

Dr. Tjønnfjord is an honoraria recipient of both Baxter Healthcare Corporation and NovoNordisk A/S
